May 2010 - PositiveID CorporationPatents Implantable Glucose Sensor
DELRAY BEACH, Fla., May 12, 2010 (BUSINESS WIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (NASDAQ: PSID) announced today that it has filed a provisional patent application with the U.S. Patent and Trademark Office covering the interface between a radio frequency ("RF") powered resonant electromechanical drive and the fluids in the interstitial space of a patient for continuous detection of glucose levels in a patient. The interface employs a resonant electromechanical drive for mass sensing and RF communication of glucose levels. This new interface represents the next evolution in the development of an implantable glucose sensor that relies on passive RF technology to continuously monitor in vivo glucose levels over an extended period of time. This new technology will effectively implement the glucose level RF sensing technology that is described in PositiveID's previously issued Patent No. 7,125,382 entitled "Embedded Bio-Sensor System." In conjunction with partner RECEPTORS LLC ("Receptors"), the Company is now in Phase II development of its implantable glucose-sensing microchip. The goal of Phase II, which is expected to be completed in mid-2010, is to optimize the sensing system for its glucose response in the presence of blood and interstitial fluid matrix components and demonstrate the integration of the components into a stable and reproducible glucose sensor.
Read More
January 2010 – BARDA Meeting
RECEPTORS LLC gave a presentation outlining the development of their point-of-care influenza sub-type ID test to the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS). BARDA provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies. BARDA’s mission includes managing the advanced research and development of medical countermeasures (MCM) for chemical, biological, radiological, and nuclear agents (CBRN), in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the PHEMCE Implementation Plan for CBRN Threats and the National Strategy for Pandemic Influenza.
December 2009 – Journal of the American Chemical Society publication
RECEPTORS LLC published a communication in the Journal of the American Chemical Society entitled "Small Molecule-Based Binding Environments: Combinatorial Construction of Microarrays for Multiplexed Affinity Screening" (Weller Roska et.al., J. Am. Chem. Soc., 2009, 131 (46), pp 16660-16662). The paper describes the construction of a combinatorial artificial receptor array (CARA) and application of the array to differentiation of proteins based on their binding patterns as a demonstration of the power of the CARA technology platform. The abstract is below and the full paper can be accessed here.
This paper describes the construction of a combinatorial artificial receptor array (CARA) and the application of the array to differentiation of proteins based on their binding patterns. Microarrays displaying 5035 unique binding environments were prepared using a library of nineteen small molecule building blocks. Each building block was equipped with a carboxylic acid handle, allowing mixtures of the building blocks to be spotted onto the surface of an amine functionalized glass slide for covalent immobilization as subunits of the binding environments. This strategy employs the microarray surface as the receptor synthesis platform, which allows for flexibility in array preparation and agility in application. An advantage of the CARA strategy is the enormous flexibility it enables in the construction of alternate microarray configurations, which facilitates rapid access to the breadth and depth of binding space. Four fluorescently labeled proteins, ubiquitin, myoglobin, α-1-acid glycoprotein and lysozyme, were incubated with the arrays to demonstrate the reproducibility of binding and the level of differentiation that can be achieved. The binding environments are stable, scalable and adaptable to other formats.
The Journal of the American Chemical Society (JACS), founded in 1879, is the flagship journal of the American Chemical Society and the preeminent journal in the field. The periodical is devoted to the publication of fundamental research papers in all areas of chemistry, providing research essential to the field.
August 2009 – American Chemical Society National Meeting, Washington, D.C.
RECEPTORS LLC’s Sensors and Diagnostics Program Leader, Rachel Weller Roska, Ph.D., presented a poster at the 238th American Chemical Society National Meeting and Exposition in Washington, D.C. The poster, entitled “Combinatorial Construction of Small Molecule-Based Binding Environments on a MALDI Target for Multiplexed Sample Fractionation and Biomarker Discovery”, describes RECEPTORS’ DIRECT-to-MALDI product prototype and its application to biomarker discovery. The poster can be viewed here.
May 31-June 4, 2009 - ASMS Conference on Mass Spectrometry, Philadelphia
We highlighted our DIRECT to MALDI™ Affinity Targets, featuring on-target fractionation of complex samples for MALDI analysis.
Direct-to-MALDI Affinity Target Poster (.pdf)
Dr. Robert E. Carlson presents RECEPTORS' poster at ASMS 2009
May 2009 - VeriChip Corporation and RECEPTORS LLC to Develop Sensor Systems to Detect Biological Threats Such as Swine Flu and other Illnesses
Companies to publish whitepaper, “An Integrated Sensor System for the Detection of Bio-Threats from Pandemics to Emerging Diseases to Bio-Terrorism,” available May 7, 2009, at www.verichipcorp.com
DELRAY BEACH, FL, and CHASKA, MN – May 6, 2009 – VeriChip Corporation (“VeriChip”) (NASDAQ: CHIP) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, today announced plans to develop surveillance and point-of-care sensor systems that will efficiently detect and identify the presence of a particular biological threat such as influenza virus, Methicillin-resistant Staphylococcus aureus (MRSA) or other illnesses. The companies will publish a white paper outlining the development of “An Integrated Sensor System for the Detection of Bio-Threats from Pandemics to Emerging Diseases to Bio-Terrorism,” which will be available May 7, 2009, on VeriChip’s website at www.verichipcorp.com.
Full Press Release (.pdf)
Sensor System for the Detection of the Bio-Threats (.pdf)
March 2009 - RECEPTORS LLC issued its flagship patent, US Patent #7,504,364 “Methods of Making Arrays and Artificial Receptors”
Abstract:
The present invention relates to artificial receptors and arrays or microarrays of artificial receptors or candidate artificial receptors. Each member of the array includes a plurality of building block compounds, typically immobilized in a spot on a support. The present invention also includes the building blocks, combinations of building blocks, arrays of building blocks, and receptors constructed of these building blocks together with a support. The present invention also includes methods of making and using these arrays and receptors.
Dr. Robert E. Carlson, inventor, US Patent #7,504,364
November 2008 - VeriChip Corporation and RECEPTORS LLC Successfully Complete Phase I Development of In Vivo Glucose Sensing RFID Microchip
Full Press Release (.pdf)
Glucose Sensor white paper (.pdf)